The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese

Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1407-11.

Abstract

The production of estrogen from androgen via the estrogen biosynthesis pathway is catalyzed by aromatase P450 (CYP19). To assess the association between breast cancer risk and a polymorphism at codon 39 Trp/Arg of the encoding gene, a case-control study was conducted at Aichi Cancer Center Hospital in Japan. Subjects were 248 histologically confirmed breast cancer patients and 603 hospital controls without cancer. Odds ratios (OR) and 95% confidence intervals (95% CI) were determined by logistic regression analysis. The allele frequency among controls was 3.8% for the C allele, and the OR (95% CI) of the polymorphism relative to TT genotype was 1.21 (0.69-2.14) for TC/CC genotypes combined. There was no association between CYP19 gene polymorphism and breast cancer risk in the study group as a whole, but homozygous and heterozygous carriers of the variant Arg allele showed a significantly increased risk of breast cancer among premenopausal women with a late age at first full-term pregnancy (OR 7.31, 95% CI 1.88-28.5) or a high body mass index (OR 2.77, 95% CI 1.12-6.87). Additional larger studies should be done to confirm that the rare CYP19 variant increases the risk of breast cancer among premenopausal Japanese women.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aromatase / genetics*
  • Base Sequence
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Codon
  • Confidence Intervals
  • DNA, Neoplasm
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease / epidemiology*
  • Genotype
  • Humans
  • Japan / epidemiology
  • Logistic Models
  • Middle Aged
  • Molecular Sequence Data
  • Neoplasms, Hormone-Dependent / epidemiology
  • Neoplasms, Hormone-Dependent / genetics*
  • Odds Ratio
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Postmenopause
  • Premenopause
  • Prevalence
  • Reference Values
  • Risk Assessment

Substances

  • Codon
  • DNA, Neoplasm
  • Aromatase